Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12873346 | 0.98 | ALDH1A1 (0.46) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL23696048 | 0.91 | MEN1 (0.40) | ALDH1A1TSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL22856475 | 0.91 | MEN1 (0.40) | ALDH1A1TSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL23696339 | 0.91 | MEN1 (0.40) | ALDH1A1TSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL13542695 | 0.89 | MEN1 (0.37) | ALDH1A1TSHRMEN1KMT2ACES2 | |
| SCHEMBL13971266 | 0.87 | HSD17B10 (0.41) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL25703927 | 0.87 | HSD17B10 (0.41) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL22526151 | 0.87 | HSD17B10 (0.41) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL12974507 | 0.87 | TSHR (0.42) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL10165857 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-9901636-B2 | Conjugate of a photosensitiser and chitosan and uses thereof | PCI BIOTECH AS (NO) | 2018-02-27 | — | — | US | disclosed |
| US-20150202293-A1 | CONJUGATE OF A PHOTOSENSITISER AND CHITOSAN AND USES THEREOF | PCI BIOTECH AS (NO) | 2015-07-23 | — | — | US | disclosed |
| US-7887835-B2 | for vascular lesion imaging and for diagnosing arteriosclerosis, ischemia with X-ray angiography and positron emission tomography; fluorinated steroid ester, glyceride compounds, phosphatidylcholine, and phosphatidylserine as membrane components of liposome | FUJIFILM CORPORATION (JP) | 2011-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202293-A1 | CONJUGATE OF A PHOTOSENSITISER AND CHITOSAN AND USES THEREOF | TLR3, CD47, TLR9 | ALDH1A1 3397/4885TSHR 4198/4885THRB 4641/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885TSHR 3319/4885THRB 1824/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885TSHR 3319/4885THRB 1824/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885TSHR 3319/4885THRB 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.